Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: StockDoc who wrote (14082)	7/11/2000 5:26:01 PM
From: aknahow	Respond to of 17367

StockDoc, a monkey agrees with an ape. Perhaps they sue the vet.?

To: StockDoc who wrote (14082)	7/11/2000 6:40:29 PM
From: Bluegreen	Respond to of 17367

Doc, patents filed only seem to cover everything. There is usually good solid reasoning and crafting by top notch legal behind most patents especially in case of a big phrama like LLY. Remember the patents have to stand up in court. While a filed of issued patent may scare a layperson it doesn't scare a top notch patent attorney unless crafted precisely, etc. In my opinion Baxter and Xoma will waste no time in responding to the LLY combo patent application.